May 1, 2025 by Thomas Sander
PharmaBlock and Alipheron Launch Ultra-Large Combinatorial Library for Drug Discovery
We are pleased to announce a strategic collaboration between PharmaBlock Sciences and Alipheron AG, culminating in the creation of an ultra-large combinatorial library. This achievement was realized through the integration of Alipheron’s advanced cheminformatics tools and PharmaBlock’s innovative chemical building blocks.
Our new strategic partnership is designed to significantly enhance drug discovery efforts by providing immediate access to a vast chemical space derived from PharmaBlock Sciences’ established physical catalogue. This collaboration has resulted in an impressive ultra-large combinatorial library of over 56 billion novel and diverse compounds. Notably, all compounds and their associated building blocks are directly available for purchase through the PharmaBlock product website.
This extensive resource is now readily accessible via Alipheron’s powerful search functionalities for ultra-large combinatorial libraries which are seamlessly integrated as plugins within DataWarrior, the widely used, open-source, and freely accessible cheminformatics platform. You can efficiently perform hit expansion and scaffold hopping with Pharos-3D, and conduct substructure and similarity searches using Hyperspace.
This development significantly increases the likelihood of successfully identifying hits and optimizing leads within this broad chemical space during the initial phases of drug discovery. Consequently, it unlocks the full potential of PharmaBlock’s physical catalogue for advanced research initiatives.
We are confident that this collaboration and the resulting ultra-large combinatorial library will serve as a valuable asset in your drug discovery pursuits. We encourage you to explore the capabilities made available through this partnership.
About the Partnering Organizations: • PharmaBlock Sciences is a preeminent provider of chemistry-based products and services that support the pharmaceutical research and development continuum. The company’s core competencies encompass process development, custom synthesis, and the supply of building blocks, alongside pilot plant and commercial-scale manufacturing of critical intermediates and active pharmaceutical ingredients (APIs). • Alipheron AG is a Swiss cheminformatics organization dedicated to the advancement of drug discovery through the development of leading-edge tools that enable innovative strategies for hit identification and lead optimization.